CPSE:BAVABiotechs
Bavarian Nordic (CPSE:BAVA) Stock Surges On Margin Strength And Contract Momentum
Bavarian Nordic walked into this earnings day with a strong run behind it. The stock is up about 20% over the past month and roughly 13% over the past week, which tells you expectations were high. The headline from the release is clear: Q2 revenue reached DKK 2,034.4m and basic earnings per share jumped to DKK 8.9, reflecting a very profitable quarter for a vaccine-focused biotech.
Under the surface, the real story for investors is margins and cash generation. Q2 gross margin sat around 61%...